Skip to main content
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2004 Nov;5(3):192–196. doi: 10.1007/s10194-004-0100-3

A one-year prospective costing study of botulinum toxin type A treatment of chronic tension headache

Fabio Palazzo 1, Francesco G Mennini 2, Laura Fioravanti 2, Laura Piasini 2, Gabriella Coloprisco 3, Paolo Martelletti 3,
PMCID: PMC3452170

Abstract

The objective was to measure the cost of botulinum toxin type A (BTX-A) treatment of chronic tension-type headache. A prospective pharmaceutical costing analysis was completed in the Day Hospital of the Regional Referral Headache Centre at Sant’Andrea Hospital in Rome, chronic tension-type headache patients were treated from February 2003 to January 2004. Patients were treated with 100 U of BTX-A every three months for one year by using the Fixed Doses Fixed Sites procedure. The cost of treatment was based on drug acquisition costs, supplies and professional time needed to administer treatment. The average cost of conventional headache medications was € 853.43 before BTX-A treatment, and € 450.47 after. The cost of BTX-A treatment was € 642.00. Adding the cost of adjunctive conventional medications brought the total cost of BTX-A treatment to € 1092.47. BTX-A treatment reduced use of conventional headache medications and expenditures although the net cost of treatment increased with BTX-A use.

Key words: Chronic tension-type headache, Costs, Botulinum toxin type A

Full Text

The Full Text of this article is available as a PDF (180.3 KB).


Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES